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M
uch in life is determined by being in the right place at the right time, while
being prepared and bold enough to seek and seize opportunities as they
present. As has been noted, I was prepared, in large part, within the Colum-
bia system. A surgical internship interlude at John Hopkins with the great Alfred Bla-
lock provided a little southern cover for my northeast background. I attribute my
boldness to my parents and great teachers: Lionel Trilling in my undergraduate years
and George Humphreys, Bob Wylie, Frank Berry, and master surgeon J. Maxwell
Chamberlain at P&S, both as a student and during my postgraduate training. I arrived
at the right place and the right time in August 1957. The University of OregonMedical
School had a brand new University Hospital with a frontier mentality and was ripe for
starting a program in cardiac surgery. I met this setting with complete confidence that I
could do anything, a characteristic often found among well-trained young surgeons.
The major focus of cardiac surgery then was on the treatment of congenital heart
disease. Extracardiac approaches for patent ductus arteriosus, aortic coarctation, and
the Blalock–Taussig shunt were well established, and the first open-heart procedure
using the heart-lung machine had been performed by Gibbon in 1953.1 Lillehei and
Varco in Minneapolis and Kirklin in Rochester, Minnesota, were moving swiftly.
My marching orders from our Chairman, J. Englebert Dunphy, were to introduce their
techniques and achieve results comparable with theirs as soon as possible. We opened
an animal laboratory in 1957 for research and team training and operated on our first
patient in the spring of 1958. The operating room was now our laboratory, and I
became fully engaged in clinical work.
Around this time, M. Lowell Edwards visited me to ask whether I would collabo-
rate with him in the development of an artificial heart. I told him it was too soon: we
did not even have satisfactory artificial valves, and both closed and open-heart proce-
dures on native valves were woefully crude. He was a ‘‘retired’’ hydraulic engineer
who held 63 patents covering a variety of things, including hydraulic lumber-debark-
ing systems and a particularly rewarding one for a fuel injection system for rapidly
climbing World War II aircraft. They were providing royalty income to support his
Edwards Development Laboratory in Portland, where his interests in fluid dynamics
were now directed to the human circulation. We struck a deal to start the project by
developing one valve at a time, taking the mitral valve first. We shook hands. In
the west, that was it. He was fragile, with early Parkinson’s disease, and wore crum-
pled slacks, a sports shirt without a tie, and a tan golfing jacket. I did not realize then
that Edwards would set a grueling pace and that I was taking on an additional full-time
job.
Early Animal Studies
The mitral valve is attached circumferentially to its annulus and tethered by a papillary
muscle apparatus that is attached to its free edges and based in the apical portion of the
left ventricle. Edwards and I made our first assumption that the tethering and a con-
tracting mitral annulus were not essential features we had to mimic. Our first design
had a single-layer sewing ring of Dacron cloth attached between 2 bonded Teflon
rings with paired hemicircular, relatively thick Silastic leaflets hinged on a crossbar,
retrospectively, a crude overbuilt prototype of today’s bileaflet mechanical valves.
Most dogs survived the operation with good cardiac function, but all died within 2
to 3 days from pulmonary edema. Autopsies showed thrombotic occlusion of the
valve and areas of dehiscence around the sewing ring. A thicker, more compliant
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iteration, which also had better flow washing of its hinges,
but thrombosis still killed the animals in 2 to 3 days.
Lowell and I decided to abandon the leaflet design and
turned our thoughts to a ball occluder with the hope that
thrombus, which we knew always formed first in injured
tissue, would stop at the margin of the valve orifice and
not affect a well-washed ball. Ball valves were common in
industry and had a little medical history. Hufnagel and col-
leagues2 had developed a device to palliate aortic regurgita-
tion, consisting of a captive ball within an acrylic tube that
could be rapidly inserted into the descending aorta, with
spiked rings at both ends to hold the tube in place. The rigid
ring and thick sewing-ring platform that we had developed
was readily adaptable to restrain the ball in the closed posi-
tion and to carry a flow-through cage to limit its forward
excursion (Figure 1).
The concept required complete re-engineering to optimize
ball-to-orifice diameters, ball travel, cage and ball materials,
and many fabrication issues, but within just 3 weeks, Lowell
delivered an implantable device. This new design had a dra-
matic short-term effect on animal survival, lengthening it to 3
to 4 weeks, when, again, all died of thrombotic occlusion
except for 1 beautiful black Labrador retriever. Autopsies
of the others showed massive thrombus piled up on the sew-
ing ring and finally reaching such thickness that it could fall
into the orifice, producing sudden obstruction. The surviving
animal remained healthy and happy and was adopted by one
of our team, which helped keep the project alive.
In the spring of 1959, as I bounded up the stairs, the
cherry blossoms caught my eye, my mind wandered, and
suddenly I thought of the solution to the thrombosis prob-
lem. Why not have a Silastic shield that could be retracted
during implantation and then snapped into place covering
the entire zone of tissue injury? We instigated the shield,
along with refinements in the cage and sewing-ring design,
and produced 80% long-term animal survival, with no earlydeaths from thrombosis. We were on the right track at last.
We could follow these animals for a few years, measuring
prosthetic valvular function and looking for specific late
complications, such as valve dehiscence, valve durability,
hemolytic anemia, infection, and others that could not be
anticipated.
Animals to Human Subjects
Dr Herbert Griswold, Oregon’s Chief of Cardiology, visited
the laboratory early in the summer of 1960 and was amazed
to find a kennel full of healthy dogs with prosthetic mitral
valves clicking away. He had many patients in the hospital
in the terminal stages of heart failure with mitral valve
disease and urged us to change our plan to early human
implantation. Dunphy said, ‘‘Do it.’’ We were suddenly thrust
into the real world of informed consent, liability, and the
need to separate manufacturing from scientific assessment,
with the first potential patients already in the hospital.
We selected the unshielded acrylic ball valve for the first
clinical implant, the logic being to use the simpler device
first; should it fail, we had the shielded valve as a backup.
Were we to have used the shielded valve first and it worked,
we would have been committed to the shield without
knowing whether it was necessary with long-term anticoa-
gulation and the human subject’s less aggressive clotting
mechanism.
Selecting patients who had no alternative therapy and
a limited life expectancy of weeks or months without treat-
ment mitigated the ethical hurdle, as did separating the busi-
ness from the university’s interests. Lowell and 3 other
investors formed Edwards Laboratories, to be based in south-
ern California, to manufacture artificial heart valves for
human use, the first such company in the world. I remained
in Oregon to continue the project as a consultant to Edwards
Laboratories but with no financial interest in the company
that could potentially discredit our findings, a decision I
have never regretted.Figure 1. Albert Starr and M. Lowell
Edwards, circa 1961, and Starr in his
office in 2007.
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The first patient was operated on in August 1960, a young
woman in her late 40s who was confined to the hospital
with end-stage rheumatic mitral valve disease after 2 previ-
ous attempts to repair her valve. The operation was easier
than in the animal laboratory, and she awakened from
anesthesia in the late afternoon with excellent circulation
parameters. That evening, I helped sit the patient up for
a portable chest radiograph. There was an air-fluid level in
the right pleural space that we interpreted as a small hemop-
neumothorax, but it was actually air in her massive left
atrium and caused a fatal stroke when she was turned on
her right side. I would never let that happen again. The sec-
ond patient was a truck dispatcher, who had previously had
2 closed commissurotomies for calcific mitral stenosis. He
was our first survivor. Fortunately, others followed.3,4 Valve
replacement was to become a frequently performed proce-
dure and rapidly extended to the aortic and tricuspid valves.
For the first 2 decades, mechanical valves prevailed, which
all required long-term anticoagulation, with its attendant
bleeding problems and an occasional valve thrombosis. In
the mid-1990s, the persistence of Alain Carpentier5 yielded
a durable bovine pericardium valve that, in common with1200 The Journal of Thoracic and Cardiovascular Surgery c Juother tissue valves, does not require anticoagulation and is
not subject to thrombotic occlusion. His valve currently is
the best choice for prosthetic replacement, except in very
young individuals.
Looking Forward
The future of valve surgery remains bright, with increasing
acceptance of mitral repair and valve-sparing aortic root
replacement. For valve replacement, the catheter-based tech-
nologies are already here, and waiting in the wings is nano-
technology blended with living autologous surfaces. We
have come a long way from the war zone of the 1960s.
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